Sign in

    Steve Brozak

    Research Analyst at WBB Securities LLC

    Steve Brozak is the Managing Partner and President of WBB Securities LLC, specializing in healthcare, biotechnology, pharmaceuticals, and medical devices equity research and investment banking. He has covered major companies including Cidara Therapeutics, CytoSorbents Corporation, and InflaRx N.V., earning top analyst rankings from StarMine, Financial Times, and The Wall Street Journal for pharmaceuticals and medical equipment, with consistent recognition for research accuracy and performance. Brozak began his finance career at firms such as Alex. Brown & Sons, Cowen & Company, Dean Witter, and Salomon Brothers before co-founding WBB Securities in 2001, and holds a B.A. and MBA from Columbia University, as well as a Doctorate in Medical Humanities from Drew University. As a FINRA-registered principal and contributor to leading publications, Brozak is known for his expertise in life sciences, stem cell therapies, and emerging infection countermeasures.

    Steve Brozak's questions to OMEROS (OMER) leadership

    Steve Brozak's questions to OMEROS (OMER) leadership • Q2 2025

    Question

    Steve Brozak of WBB Securities LLC asked for a comparison between the financial modeling for the upcoming narsoplimab launch and the past launch of OMIDRIA. He also inquired about the level of urgency and enthusiasm among clinicians for narsoplimab, given the severe condition of TA-TMA patients.

    Answer

    Gregory Demopulos, Founder, Chairman, CEO & President, explained that the narsoplimab launch is more focused than OMIDRIA's due to a smaller number of transplant centers, but declined to provide specific financial projections at this time. Nadia Dac, CCO, added that physicians are eagerly awaiting an approved therapy for this lethal complication and that feedback from the Expanded Access Program has been very positive, highlighting a significant unmet need.

    Ask Fintool Equity Research AI

    Steve Brozak's questions to SCYNEXIS (SCYX) leadership

    Steve Brozak's questions to SCYNEXIS (SCYX) leadership • Q2 2022

    Question

    Steve Brozak asked for a refresher on the typical patient journey, specifically the number of visits and fluconazole scripts a patient has before using BREXAFEMME, and inquired about the company's strategy and inroads with concierge medicine.

    Answer

    President and CEO Dr. Marco Taglietti explained that about 40% of patients on fluconazole require at least one additional prescription, leading to frustration. He highlighted new data from the CANDLE sub-study where over 70% of patients who failed three doses of fluconazole responded to a single day of BREXAFEMME. Chief Commercial Officer Christine Coyne added that physicians are relieved to have an option that reduces patient callbacks. Regarding concierge medicine, Coyne stated that while the marketing team is evaluating it, resources are currently focused on initiatives with a more established ROI.

    Ask Fintool Equity Research AI

    Steve Brozak's questions to SCYNEXIS (SCYX) leadership • Q4 2021

    Question

    Steve Brozak of WBB Securities asked for direct feedback from clinicians regarding refractory patients who experienced significant changes in symptoms after using BREXAFEMME and how that feedback is used in messaging. He also inquired about the impact of recent scientific publications on Candida glabrata and whether more such publications highlighting the drug's advantages are expected.

    Answer

    CEO Dr. Marco Taglietti clarified that the company does not promote for the unapproved recurrent VVC indication but highlighted promising CANDLE study data showing over 70% of fluconazole-failure patients had significant improvement. Chief Medical Officer Dr. David Angulo affirmed that the drug's activity against non-albicans species like Candida glabrata is a key attribute and expects more publications to emerge, which is also critical for the hospital franchise.

    Ask Fintool Equity Research AI